Samsung Set to Begin HBM4 Production for Nvidia and AMD 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
ROCKVILLE, Md., May 10, 2017 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the Gene Therapy and Gene Editing panel discussion at the Bank of America Merrill Lynch 2017 Health Care Conference on Wednesday, May 17, 2017 at 1:40 p.m. PT at the Encore Wynn in Las Vegas, NV. In addition, REGENXBIO senior management will be holding one-on-one meetings at the conference.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
CONTACT: Investors Heather Savelle, 646-395-3734 [email protected] Media Adam Pawluk, 202-591-4063 [email protected]
